Jpmorgan Chase & CO Mannkind Corp Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Mannkind Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 113,188 shares of MNKD stock, worth $802,502. This represents 0.0% of its overall portfolio holdings.

Number of Shares

113,188

Previous 112,799 0.34%

Holding current value

$802,502

Previous $510,000 15.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$4.05 - $5.43 $1,575 - $2,112	389 Added 0.34%	113,188 $590,000
Q1 2024 May 10, 2024	SELL	$3.25 - $5.27 $206,722 - $335,208	-63,607 Reduced 36.06%	112,799 $510,000
Q4 2023 Feb 12, 2024	BUY	$3.34 - $4.29 $2,281 - $2,930	683 Added 0.39%	176,406 $642,000
Q3 2023 Nov 14, 2023	SELL	$3.91 - $5.45 $751,740 - $1.05 Million	-192,261 Reduced 52.25%	175,723 $725,000
Q2 2023 Aug 11, 2023	BUY	$3.72 - $4.79 $638,333 - $821,940	171,595 Added 87.38%	367,984 $1.5 Million
Q1 2023 May 18, 2023	BUY	$3.95 - $5.63 $770,273 - $1.1 Million	195,006 Added 14100.22%	196,389 $805,000
Q1 2023 May 11, 2023	SELL	$3.95 - $5.63 $1.59 Million - $2.26 Million	-401,275 Reduced 99.66%	1,383 $5,000
Q4 2022 Feb 13, 2023	BUY	$3.02 - $5.37 $748,380 - $1.33 Million	247,808 Added 160.03%	402,658 $2.12 Million
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $26,138 - $38,027	8,742 Added 5.98%	154,850 $478,000
Q2 2022 Aug 11, 2022	SELL	$2.67 - $4.77 $3,230 - $5,771	-1,210 Reduced 0.82%	146,108 $556,000
Q1 2022 May 11, 2022	BUY	$2.62 - $4.45 $74,717 - $126,905	28,518 Added 24.01%	147,318 $542,000
Q4 2021 Feb 10, 2022	BUY	$4.05 - $5.37 $35,822 - $47,497	8,845 Added 8.04%	118,800 $519,000
Q3 2021 Nov 12, 2021	BUY	$3.89 - $5.48 $427,724 - $602,553	109,955 New	109,955 $479,000

Others Institutions Holding MNKD

# of Institutions

229

Shares Held

133M

Call Options Held

1.43M

Put Options Held

849K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.82B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Mannkind Corp Transaction History